Takeda Pharmaceutical Co. said it will acquire Swiss drugmaker Nycomed for about $13.7 billion.
Takeda to acquire Swiss drugmaker Nycomed
The acquisition, which excludes Nycomed's dermatology business in the U.S., will bolster Osaka, Japan-based Takeda's presence in Europe and emerging markets, according to a news release (PDF). Takeda said the acquisition, expected to close in September, will boost revenue by 30% annually.
Nycomed, headquartered in Zurich, includes in its product portfolio prescription and over-the-counter drugs that treat pain, respiratory diseases and acid-related gastrointestinal disorders. It was acquired by Nordic Capital and other co-investors in 2005.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.